



CREATE TREATMENTS THAT ARE MOST EFFECTIVE

CAS FORMULUS® MONTELUKAST SODIUM USE CASE

CAS Formulus® streamlines the formulation process addressing shelf life, regulatory, and compatibility concerns in a single solution.

Mine data insights impacting formulation innovation

Ground your decisions in solid insights

Popular baseline ingredient montelukast sodium (CAS RN 151767-02-01) is frequently used by formulation scientists to treat asthma.

Developing pediatric chewables that taste good can be difficult, complex, and time consuming. This is especially true for asthma patients who seek oral alternatives to inhalers. To induce patient compliance, it's necessary to include other ingredients with montelukast sodium to make the product palatable. CAS Formulus helps you do that.







Q How do I make this formulation ingredient work for a patient?


A The primary job of a pharmaceutical formulation scientist is to develop a safe and effective medicine that treats a patient's ailment. Data displayed in CAS Formulus allows you to make a quick decision about montelukast sodium's function, amount reported, and optionality.

Cyclopropaneacetic acid, 1-[[[(1 <i>R</i>)-1-[3-[(1 <i>E</i>)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt (1:1)	active agent	5 mg	Mandatory
Mannitol	excipient	297.5 mg	Mandatory
modified karaya gum	diluent	150 mg	Mandatory
hydroxy propyl cellulose	binder	12.5 mg	Mandatory
Sodium carboxymethyl starch	disintegrant	20 mg	Mandatory
Aspartame	excipient	5 mg	Mandatory
Vanillin	excipient	5 mg	Mandatory
Water	excipient	-	Mandatory
Magnesium stearate	excipient	5 mg	Mandatory

Q Is my formulation going to be compatible with other active or inactive ingredients?

A Formulation scientists who are focused on innovation and not generics can use the *Commonly Formulated With* feature within CAS Formulus to seek and find connections between active and inactive ingredients.

CAS Formulus	
Substances ▾	   
^ Commonly Formulated With	
Ingredient/Substance	
557-04-0 Magnesium stearate	View Formulations
7732-18-5 Water	View Formulations
9004-34-6 Cellulose	View Formulations
69-65-8 Mannitol	View Formulations
74811-65-7 Croscarmellose sodium	View Formulations
9004-64-2 Hydroxypropyl cellulose	View Formulations
1309-37-1 Iron oxide (Fe ₂ O ₃)	View Formulations
9004-65-3 Hydroxypropyl methyl cellulose	View Formulations
22839-47-0 Aspartame	View Formulations
25322-68-3 Polyethylene glycol	View Formulations
7631-86-9 Silica	View Formulations
56038-13-2 Sucralose	View Formulations
13463-67-7 Titania	View Formulations
130018-87-0 Levocetirizine dihydrochloride	View Formulations
9003-39-8 Poly(vinylpyrrolidone)	View Formulations
64044-51-5 Lactose, monohydrate	View Formulations
9063-38-1 Sodium carboxymethyl starch	View Formulations
14807-96-6 Talc (Mg ₃ H ₂ (SiO ₃) ₄)	View Formulations
9005-25-8 Starch	View Formulations
63-42-3 (+)-Lactose	View Formulations



montelukast sodium
(CAS RN 151767-02-1)

• Na



Q Is my product compliant with government regulatory agencies?

A The pharmaceutical industry is highly regulated, with many rules and regulations to protect the health and well-being of the public. Therefore, the aim of the pharmaceutical industry is to identify and develop a drug product that can be customized to meet diverse market requirements.

CAS Formulus pairs substance information with important regulatory information for various countries including comprehensive FDA Orange Book data.

CAS Formulus		Substances ▾	🔍	💬	🕒	👤
^ Regulatory Information						
ANMAT	FDA Orange Book	Japanese Approved Drugs List				
Delivery Form	Strength	Route	Application	Approval Event	Event Date	Additional Information
GRANULE	EQ 4MG BASE/PACKET	ORAL	Type: NDA Number: 021409 Applicant: MERCK RESEARCH LABORATORIES DIV MERCK CO INC	Approval	Jul 26, 2002	Reference Listed Drug: Yes Reference Standard: Yes Marketing Status: RX
GRANULE	EQ 4MG BASE/PACKET	ORAL	Type: ANDA Number: 090955 Applicant: TEVA PHARMACEUTICALS USA	Approval	Aug 3, 2012	Reference Listed Drug: No Reference Standard: No Marketing Status: RX
GRANULE	EQ 4MG BASE/PACKET	ORAL	Type: ANDA Number: 202776 Applicant: MYLAN PHARMACEUTICALS INC	Approval	Dec 18, 2012	Reference Listed Drug: No Reference Standard: No Marketing Status: DISCN
GRANULE	EQ 4MG BASE/PACKET	ORAL	Type: ANDA Number: 202906 Applicant: DR REDDYS LABORATORIES LTD	Approval	Sep 17, 2012	Reference Listed Drug: No Reference Standard: No Marketing Status: RX
GRANULE	EQ 4MG BASE/PACKET	ORAL	Type: ANDA Number: 203438 Applicant: AJANTA PHARMA LTD	Approval	Jul 31, 2015	Reference Listed Drug: No Reference Standard: No Marketing Status: RX



Built by the creators of CAS SciFinder[®]
and the CAS REGISTRY[®] database

Learn more at cas.org

CAS Formulus is a solution within the CAS SciFinder Discovery Platform, an enterprise solution created to help get discoveries to market faster and optimize profitability. CAS SciFinder Discovery Platform provides researchers with the information they need to avoid surprises and make smart investments with insight into the latest discoveries and competitive intelligence

Connect with us at cas.org